Uterine Cancer (UC)
Uterine cancer (UC) is a significant health concern affecting women worldwide. At our company, we are dedicated to advancing the field of UC therapy development through our comprehensive diagnostics, animal model development, and preclinical research services.
Introduction to Uterine Cancer (UC)
Uterine cancer, also known as womb cancer, originates in the lining of the uterus and the muscles or support tissue of the uterus. The age-standardized incidence rate (ASIR) of UC was 9.99/100 000 (95%CI: 9.12-11.02). UC occurs when abnormal cells in the endometrium grow uncontrollably, forming a tumor. There are several types of uterine cancer:
- Endometrial cancer (endometrial adenocarcinoma)
-Serous adenocarcinoma
-Adenosquamous carcinoma
-Uterine carcinosarcoma
- Uterine sarcoma
-Uterine leiomyosarcoma
-Endometrial stromal sarcomas
-Undifferentiated sarcoma
Pathogenesis of Uterine Cancer (UC)
The exact cause of UC remains unclear, but several risk factors have been identified. One of the main risk factors is elevated exposure to estrogen, either due to hormonal imbalances, prolonged use of estrogen-only hormone replacement therapy, or obesity. Other risk factors include age, family history, certain genetic mutations (such as Lynch syndrome), and a history of certain conditions like polycystic ovary syndrome (PCOS) or diabetes.
Fig.1 Trend of combination therapy of uterine cancer (UC). (Syeda, Sbaa, et al., 2019)Targets of Uterine Cancer (UC) Therapy
Estrogen Receptors (ER)
Estrogen receptors play a vital role in the development and progression of UC. Targeting these receptors can help regulate estrogen signaling and inhibit tumor growth.
Progesterone Receptors (PR)
Progesterone receptors are involved in the regulation of endometrial tissue. Modulating the activity of PR can influence the growth and survival of UC cells.
PI3K/AKT/mTOR Pathway
This signaling pathway is frequently dysregulated in UC, leading to abnormal cell growth and survival. Inhibiting this pathway can be a potential therapeutic strategy.
HER2/neu
Overexpression of the HER2/neu protein is observed in a subset of UC cases. Targeting HER2/neu can help control tumor growth and improve outcomes.
Therapy Development of Uterine Cancer (UC)
- Hormone Therapy
Hormone therapy aims to alter hormone levels in the body to slow down or stop the growth of cancer cells. It is primarily used for estrogen receptor-positive uterine cancer (UC).
- Targeted Therapy
Targeted therapy drugs specifically target certain molecular targets involved in UC, such as mTOR inhibitors, monoclonal antibodies, and signal transduction inhibitors.
Our Services
By focusing on discovered molecular targets and leveraging cutting-edge technologies, our company provides effective customized diagnostics and therapeutic development services to the pharmaceutical industry.
Therapy Development Platforms
Animal Model Development Services
| Genetically Engineered Models | |||
|---|---|---|---|
| Through precise gene manipulation, we can mimic the genetic alterations seen in human uterine cancer, providing researchers with reliable models for their studies. We employ rigorous phenotypic characterization techniques to validate the generated uterine cancer models. This includes histopathological analysis, molecular profiling, and functional assays to ensure that the models faithfully recapitulate the key features of human uterine cancer. | |||
| Optional Models |
|
|
|
| Optional Species | Mouse, Rat, Others | ||
Understanding the pharmacokinetics and pharmacodynamics of potential UC therapies is critical for optimizing therapeutic regimens. Our experts conduct detailed studies to assess these parameters and inform dosing strategies. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
- Syeda, Sbaa, et al. "Chemotherapy, radiation, or combination therapy for stage III uterine cancer." Obstetrics & Gynecology 134.1 (2019): 17-29.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.